{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T18:01:29Z","timestamp":1791655289348,"version":"4.3.4"},"reference-count":57,"publisher":"Oxford University Press (OUP)","issue":"Supplement_8","license":[{"start":{"date-parts":[[2019,12,9]],"date-time":"2019-12-09T00:00:00Z","timestamp":1575849600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,12,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Shigella causes morbidity and mortality worldwide, primarily affecting young children living in low-resource settings. It is also of great concern due to increasing antibiotic resistance, and is a priority organism for the World Health Organization. A Shigella vaccine would decrease the morbidity and mortality associated with shigellosis, improve child health, and decrease the need for antibiotics. Controlled human infection models (CHIMs) are useful tools in vaccine evaluation for early up- or down-selection of vaccine candidates and potentially useful in support of licensure. Over time, the methods employed in these models have become more uniform across sites performing CHIM trials, although some differences in conduct persist. In November 2017, a Shigella CHIM workshop was convened in Washington, District of Columbia. Investigators met to discuss multiple aspects of these studies, including study procedures, clinical and immunological endpoints, and shared experiences. This article serves as a uniform procedure by which to conduct Shigella CHIM studies.<\/jats:p>","DOI":"10.1093\/cid\/ciz892","type":"journal-article","created":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T19:27:08Z","timestamp":1569958028000},"page":"S580-S590","source":"Crossref","is-referenced-by-count":32,"title":["Consensus Report on Shigella Controlled Human Infection Model: Conduct of Studies"],"prefix":"10.1093","volume":"69","author":[{"given":"Kawsar R","family":"Talaat","sequence":"first","affiliation":[{"name":"Center for Immunization Research, Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A Louis","family":"Bourgeois","sequence":"additional","affiliation":[{"name":"Enteric Vaccine Initiative, PATH, Washington, District of Columbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert W","family":"Frenck","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilbur H","family":"Chen","sequence":"additional","affiliation":[{"name":"Center for Vaccine Development, University of Maryland School of Medicine, Baltimore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Calman A","family":"MacLennan","sequence":"additional","affiliation":[{"name":"Bill & Melinda Gates Foundation, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark S","family":"Riddle","sequence":"additional","affiliation":[{"name":"F. Edward H\u00e9bert School of Medicine, Uniformed Services University, Bethesda"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akamol E","family":"Suvarnapunya","sequence":"additional","affiliation":[{"name":"Department of Enteric Infections, Bacterial Diseases Branch, Walter Reed Army Institute of Research, Silver Spring"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica L","family":"Brubaker","sequence":"additional","affiliation":[{"name":"Global Disease Epidemiology and Control Program, Department of International Health, Johns Hopkins Bloomberg School of Public Health"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen L","family":"Kotloff","sequence":"additional","affiliation":[{"name":"Division of Infectious Disease and Tropical Pediatrics, Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chad K","family":"Porter","sequence":"additional","affiliation":[{"name":"Enteric Disease Department, Naval Medical Research Center, Silver Spring, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,12,9]]},"reference":[{"key":"2019120911271329600_CIT0001","doi-asserted-by":"crossref","first-page":"57","DOI":"10.2307\/4585157","article-title":"Studies of the acute diarrheal diseases; etiology","volume":"60","author":"Hardy","year":"1945","journal-title":"Public Health Rep"},{"key":"2019120911271329600_CIT0002","first-page":"651","article-title":"Global burden of Shigella infections: implications for vaccine development and implementation of control strategies","volume":"77","author":"Kotloff","year":"1999","journal-title":"Bull World Health Organ"},{"key":"2019120911271329600_CIT0003","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0140-6736(13)60844-2","article-title":"Burden and aetiology of diarrhoeal disease in infants and young children in developing countries (the Global Enteric Multicenter Study, GEMS): a prospective, case-control study","volume":"382","author":"Kotloff","year":"2013","journal-title":"Lancet"},{"key":"2019120911271329600_CIT0004","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1016\/S0140-6736(16)31529-X","article-title":"Use of quantitative molecular diagnostic methods to identify causes of diarrhoea in children: a reanalysis of the GEMS case-control study","volume":"388","author":"Liu","year":"2016","journal-title":"Lancet"},{"key":"2019120911271329600_CIT0005","doi-asserted-by":"crossref","first-page":"e564","DOI":"10.1016\/S2214-109X(15)00151-5","article-title":"Pathogen-specific burdens of community diarrhoea in developing countries: a multisite birth cohort study (MAL-ED)","volume":"3","author":"Platts-Mills","year":"2015","journal-title":"Lancet Glob Health"},{"key":"2019120911271329600_CIT0006","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/S1473-3099(17)30276-1","article-title":"Estimates of global, regional, and national morbidity, mortality, and aetiologies of diarrhoeal diseases: a systematic analysis for the Global Burden of Disease Study 2015","volume":"17","author":"GBD Diarrhoeal Diseases Collaborators","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"2019120911271329600_CIT0007","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/S0140-6736(17)33296-8","article-title":"Shigellosis","volume":"391","author":"Kotloff","year":"2018","journal-title":"Lancet"},{"key":"2019120911271329600_CIT0008","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/S1473-3099(18)30475-4","article-title":"Morbidity and mortality due to Shigella and enterotoxigenic Escherichia coli diarrhoea: the Global Burden of Disease Study 1990-2016","volume":"18","author":"Khalil","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"2019120911271329600_CIT0009","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1542\/peds.73.6.799","article-title":"Effects of diarrhea associated with specific enteropathogens on the growth of children in rural Bangladesh","volume":"73","author":"Black","year":"1984","journal-title":"Pediatrics"},{"key":"2019120911271329600_CIT0010","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1097\/INF.0000000000000351","article-title":"Effects of Shigella-, Campylobacter- and ETEC-associated diarrhea on childhood growth","volume":"33","author":"Lee","year":"2014","journal-title":"Pediatr Infect Dis J"},{"key":"2019120911271329600_CIT0011","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.7205\/MILMED-D-17-00064","article-title":"Travelers\u2019 diarrhea: an update on the incidence, etiology, and risk in military deployments and similar travel populations","volume":"182","author":"Porter","year":"2017","journal-title":"Mil Med"},{"key":"2019120911271329600_CIT0012","volume-title":"WHO preferred product characteristics (PPCs)","author":"World Health Organization","year":"2018"},{"key":"2019120911271329600_CIT0013","volume-title":"WHO publishes list of bacteria for which new antibiotics are urgently needed","author":"World Health Organization","year":"2017"},{"key":"2019120911271329600_CIT0014","doi-asserted-by":"crossref","first-page":"2887","DOI":"10.1016\/j.vaccine.2016.02.075","article-title":"Status of vaccine research and development for Shigella","volume":"34","author":"Mani","year":"2016","journal-title":"Vaccine"},{"key":"2019120911271329600_CIT0015","doi-asserted-by":"crossref","first-page":"4075","DOI":"10.1128\/IAI.59.11.4075-4083.1991","article-title":"Small-animal model to measure efficacy and immunogenicity of Shigella vaccine strains","volume":"59","author":"Hartman","year":"1991","journal-title":"Infect Immun"},{"key":"2019120911271329600_CIT0016","doi-asserted-by":"crossref","first-page":"6798","DOI":"10.1016\/j.vaccine.2017.08.030","article-title":"Improving chances for successful clinical outcomes with better preclinical models","volume":"35","author":"Wenzel","year":"2017","journal-title":"Vaccine"},{"key":"2019120911271329600_CIT0017","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1017\/S0950268812001677","article-title":"The Shigella human challenge model","volume":"141","author":"Porter","year":"2013","journal-title":"Epidemiol Infect"},{"key":"2019120911271329600_CIT0018","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1016\/S0140-6736(17)32149-9","article-title":"Efficacy and immunogenicity of a Vi-tetanus toxoid conjugate vaccine in the prevention of typhoid fever using a controlled human infection model of Salmonella Typhi: a randomised controlled, phase 2b trial","volume":"390","author":"Jin","year":"2017","journal-title":"Lancet"},{"key":"2019120911271329600_CIT0019","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1093\/cid\/ciw145","article-title":"Single-dose live oral cholera vaccine CVD 103-HgR protects against human experimental infection with Vibrio cholerae O1 El Tor","volume":"62","author":"Chen","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2019120911271329600_CIT0020","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1001\/jama.1946.02870420002002","article-title":"Experimental human bacillary dysentery; polyvalent dysentery vaccine in its prevention","volume":"132","author":"Shaughnessy","year":"1946","journal-title":"J Am Med Assoc"},{"key":"2019120911271329600_CIT0021","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1093\/infdis\/119.3.296","article-title":"The response of man to virulent Shigella flexneri 2a","volume":"119","author":"DuPont","year":"1969","journal-title":"J Infect Dis"},{"key":"2019120911271329600_CIT0022","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1093\/infdis\/125.1.12","article-title":"Immunity in shigellosis. II. Protection induced by oral live vaccine or primary infection","volume":"125","author":"DuPont","year":"1972","journal-title":"J Infect Dis"},{"key":"2019120911271329600_CIT0023","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1093\/infdis\/155.6.1260","article-title":"Prevention of shigellosis by a Salmonella Typhi\u2013Shigella sonnei bivalent vaccine","volume":"155","author":"Black","year":"1987","journal-title":"J Infect Dis"},{"key":"2019120911271329600_CIT0024","doi-asserted-by":"crossref","first-page":"3437","DOI":"10.1128\/IAI.67.7.3437-3443.1999","article-title":"Vaccination against shigellosis with attenuated Shigella flexneri 2a strain SC602","volume":"67","author":"Coster","year":"1999","journal-title":"Infect Immun"},{"key":"2019120911271329600_CIT0025","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/0264-410X(94)00011-B","article-title":"Evaluation of the safety, immunogenicity, and efficacy in healthy adults of four doses of live oral hybrid Escherichia coli\u2013Shigella flexneri 2a vaccine strain EcSf2a-2","volume":"13","author":"Kotloff","year":"1995","journal-title":"Vaccine"},{"key":"2019120911271329600_CIT0026","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/infdis\/127.3.261","article-title":"Pathogenesis of Shigella dysenteriae 1 (Shiga) dysentery","volume":"127","author":"Levine","year":"1973","journal-title":"J Infect Dis"},{"key":"2019120911271329600_CIT0027","unstructured":"Harro C , RiddleMS, KaminskiRW, et al, eds. Shigella flexneri 2a Invaplex 50 intranasal vaccine phase 2b challenge study. In: 5th International Vaccines for Enteric Diseases Conference, M\u00e1laga, Spain, 2009."},{"key":"2019120911271329600_CIT0028","unstructured":"Talaat KR , AlaimoC, BourgeoisAL, et al, eds. Flexyn2a, a candidate bioconjugate vaccine against Shigella flexneri 2a, induces protective immune response in a controlled human infection model. In: Vaccines for Enteric Diseases Conference,Albufeira, Portugal, 2017."},{"key":"2019120911271329600_CIT0029","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.4049\/jimmunol.164.4.2221","article-title":"Production of IFN-gamma and IL-10 to Shigella invasins by mononuclear cells from volunteers orally inoculated with a Shiga toxin-deleted Shigella dysenteriae type 1 strain","volume":"164","author":"Samandari","year":"2000","journal-title":"J Immunol"},{"key":"2019120911271329600_CIT0030","doi-asserted-by":"crossref","first-page":"7040","DOI":"10.1016\/j.vaccine.2012.09.061","article-title":"Establishment of a Shigella sonnei human challenge model in Thailand","volume":"30","author":"Bodhidatta","year":"2012","journal-title":"Vaccine"},{"key":"2019120911271329600_CIT0031","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1128\/CVI.00665-15","article-title":"Clinical trial of an oral live Shigella sonnei vaccine candidate, WRSS1, in Thai adults","volume":"23","author":"Pitisuttithum","year":"2016","journal-title":"Clin Vaccine Immunol"},{"key":"2019120911271329600_CIT0032","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1093\/phe\/phv026","article-title":"Ethical criteria for human challenge studies in infectious diseases","volume":"9","author":"Bambery","year":"2016","journal-title":"Public Health Ethics"},{"key":"2019120911271329600_CIT0033","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1136\/jme.2003.004440","article-title":"Challenge studies of human volunteers: ethical issues","volume":"30","author":"Hope","year":"2004","journal-title":"J Med Ethics"},{"key":"2019120911271329600_CIT0034","doi-asserted-by":"crossref","first-page":"e312","DOI":"10.1016\/S1473-3099(18)30177-4","article-title":"Experimental infection of human volunteers","volume":"18","author":"Roestenberg","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"2019120911271329600_CIT0035","author":"US Food and Drug Administration","year":"2016"},{"key":"2019120911271329600_CIT0036","author":"US Food and Drug Administration","year":"2018"},{"key":"2019120911271329600_CIT0037","author":"US Food and Drug Administration","year":"2018"},{"key":"2019120911271329600_CIT0038","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1086\/322664","article-title":"The ethical challenge of infection-inducing challenge experiments","volume":"33","author":"Miller","year":"2001","journal-title":"Clin Infect Dis"},{"key":"2019120911271329600_CIT0039","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1128\/CVI.00224-16","article-title":"Safety and immunogenicity of a candidate bioconjugate vaccine against Shigella flexneri 2a administered to healthy adults: a single-blind, randomized phase I study","volume":"23","author":"Riddle","year":"2016","journal-title":"Clin Vaccine Immunol"},{"key":"2019120911271329600_CIT0040","doi-asserted-by":"crossref","first-page":"6624","DOI":"10.1128\/IAI.68.12.6624-6632.2000","article-title":"Isolation and characterization of a Shigella flexneri invasin complex subunit vaccine","volume":"68","author":"Turbyfill","year":"2000","journal-title":"Infect Immun"},{"key":"2019120911271329600_CIT0041","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1038\/ajg.2010.56","article-title":"Validation of symptom-based diagnostic criteria for irritable bowel syndrome: a critical review","volume":"105","author":"Whitehead","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"2019120911271329600_CIT0042","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1053\/j.gastro.2006.03.008","article-title":"The functional gastrointestinal disorders and the Rome III process","volume":"130","author":"Drossman","year":"2006","journal-title":"Gastroenterology"},{"key":"2019120911271329600_CIT0043","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00412-16","article-title":"Functional and antigen-specific serum antibody levels as correlates of protection against shigellosis in a controlled human challenge study","volume":"24","author":"Shimanovich","year":"2017","journal-title":"Clin Vaccine Immunol"},{"key":"2019120911271329600_CIT0044","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.1128\/IAI.71.5.2775-2786.2003","article-title":"Complete genome sequence and comparative genomics of Shigella flexneri serotype 2a strain 2457T","volume":"71","author":"Wei","year":"2003","journal-title":"Infect Immun"},{"key":"2019120911271329600_CIT0045","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1038\/ng.2369","article-title":"Shigella sonnei genome sequencing and phylogenetic analysis indicate recent global dissemination from Europe","volume":"44","author":"Holt","year":"2012","journal-title":"Nat Genet"},{"key":"2019120911271329600_CIT0046","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1093\/infdis\/159.6.1126","article-title":"Inoculum size in shigellosis and implications for expected mode of transmission","volume":"159","author":"DuPont","year":"1989","journal-title":"J Infect Dis"},{"key":"2019120911271329600_CIT0047","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1093\/cid\/ciu468","article-title":"Shigella isolates from the Global Enteric Multicenter Study inform vaccine development","volume":"59","author":"Livio","year":"2014","journal-title":"Clin Infect Dis"},{"key":"2019120911271329600_CIT0048","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1128\/JCM.02713-12","article-title":"Quantitative PCR for detection of Shigella improves ascertainment of Shigella burden in children with moderate-to-severe diarrhea in low-income countries","volume":"51","author":"Lindsay","year":"2013","journal-title":"J Clin Microbiol"},{"key":"2019120911271329600_CIT0049","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1086\/591703","article-title":"Effect of adjunctive loperamide in combination with antibiotics on treatment outcomes in traveler's diarrhea: a systematic review and meta-analysis","volume":"47","author":"Riddle","year":"2008","journal-title":"Clin Infect Dis"},{"key":"2019120911271329600_CIT0050","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1093\/cid\/cix693","article-title":"Trial Evaluating Ambulatory Therapy of Travelers' Diarrhea (TrEAT TD) Study: a randomized controlled trial comparing 3 single-dose antibiotic regimens with loperamide","volume":"65","author":"Riddle","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2019120911271329600_CIT0051","doi-asserted-by":"crossref","first-page":"727","DOI":"10.7326\/0003-4819-117-9-727","article-title":"Treatment of shigellosis: III. Comparison of one- or two-dose ciprofloxacin with standard 5-day therapy. A randomized, blinded trial","volume":"117","author":"Bennish","year":"1992","journal-title":"Ann Intern Med"},{"key":"2019120911271329600_CIT0052","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/0163-4453(92)93849-L","article-title":"Single-dose ciprofloxacin for shigellosis in adults","volume":"25","author":"Bhattacharya","year":"1992","journal-title":"J Infect"},{"key":"2019120911271329600_CIT0053","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1517\/14656566.4.8.1315","article-title":"An evaluation of current shigellosis treatment","volume":"4","author":"Bhattacharya","year":"2003","journal-title":"Expert Opin Pharmacother"},{"key":"2019120911271329600_CIT0054","doi-asserted-by":"crossref","first-page":"e0194325","DOI":"10.1371\/journal.pone.0194325","article-title":"Clinical endpoints in the controlled human challenge model for Shigella: a call for standardization and the development of a disease severity score","volume":"13","author":"Porter","year":"2018","journal-title":"PLoS One"},{"key":"2019120911271329600_CIT0055","first-page":"457","article-title":"Studies on vaccination against bacillary dysentery. 6. Protection of children by oral immunization with streptomycin-dependent Shigella strains","volume":"45","author":"Mel","year":"1971","journal-title":"Bull World Health Organ"},{"key":"2019120911271329600_CIT0056","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/0264-410X(90)90094-3","article-title":"Studies in volunteers to evaluate candidate Shigella vaccines: further experience with a bivalent Salmonella Typhi\u2013Shigella sonnei vaccine and protection conferred by previous Shigella sonnei disease","volume":"8","author":"Herrington","year":"1990","journal-title":"Vaccine"},{"key":"2019120911271329600_CIT0057","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1093\/oxfordjournals.aje.a116134","article-title":"Epidemiologic patterns of acute diarrhea and endemic Shigella infections in children in a poor periurban setting in Santiago, Chile","volume":"134","author":"Ferreccio","year":"1991","journal-title":"Am J Epidemiol"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/69\/Supplement_8\/S580\/31292405\/ciz892.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/69\/Supplement_8\/S580\/31292405\/ciz892.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,30]],"date-time":"2022-09-30T19:08:18Z","timestamp":1664564898000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/69\/Supplement_8\/S580\/5670765"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,9]]},"references-count":57,"journal-issue":{"issue":"Supplement_8","published-online":{"date-parts":[[2019,12,9]]},"published-print":{"date-parts":[[2019,12,9]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciz892","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,12,15]]},"published":{"date-parts":[[2019,12,9]]}}}